anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
Applicants have disclosed a wireless method for remotely monitoring the physiological status of ambulatory patients by using at least one &#34;cloud&#34; server. Physiological data, including ECG data, is collected by a device worn by a patient and then wirelessly transmitted (e.g., via a cell phone) to the server(s). The same device can alert a patient as to trouble, whereas the server can do the same to clinicians. Remote processing of electrocardiograms (&#34;ECG&#34;) is achieved, in part, by data streaming packet lengths acquired over no less than 3 seconds - 3 seconds is typically equivalent to about 3 cardiac cycles (heartbeats) - to provide the quickest response time by clinicians to try to save a heart patient&#39;s life. Other physiological data (e.g., blood pressure, respiration, oxygen saturation) are monitored by the device, so medical help can be obtained when needed. In this manner, any sudden onset of vicissitudes in a patient&#39;s well being may be detected using physiological information from a parallel combination of vital signs, and transmitted to the care-giver and patient in a near real-time fashion.
FIELD: medical biotechnology. SUBSTANCE: the innovation deals with the method to test compounds able to induce STF-I transcription. For this purpose the cells of pancreatic insulae which express STF-I/lac Z hybrid gene are isolated, then the impact of different compounds upon STF-I expression is estimated by adding the suggested compound to STF-I/lac Z-expressing cells. Then, due to calorimetric assay a qualitative estimation of lac Z-activity is conducted both in control and treated cells. Due to this method it could be screened the great number of compounds and STF-I- inducing ones could, also, be easily identified. Another aspect of innovation deals with the method to use STF-I promoter to trace insulin-producing cells of pancreatic insulae in vivo. This method uses protein with fluorescence in a green spectrum area as an indicator. Introduction of transgene named &#34;STF-I-protein with green fluorescence&#34; enables to isolate, quickly and efficiently, insulin-producing cells out of pancreas. EFFECT: broadened assortment of preparations to regulate neuroendocrine system. 9 cl, 13 ex
277,302. Chemische Fabric auf Actien, vorm. E. Schering. Sept. 11, 1926. [Convention date]. Divided on and addition fo 271,492. Medicines for internal use.-Relates to the process for obtaining active medical products from vegetable organisms described in the parent Specification, and consists in particular applications of the process as follows: (1) Cherries are comminuted, extracted with ethyl or methyl alcohol, and the extract is filtered, concentrated, repeatedly treated with alcohol to precipitate impurities, and finally evaporated &#39;to dryness and the residue extracted with ether: (2) comminuted parsley root is extracted with warm methyl alcohol and the extract filtered, evaporated to dryness, dissolved in water and the aqueous solution extracted with ether; (3) yeast, free from albumen, obtained by the process of Buchner and Gruber according to which yeast is liquefied bv mixing with a small quantity of an organic solvent such as ether and the albumen separated by boiling and filtration, is treated with ether, the solution evaporated. the residue dissolved in acetone. the acetone evaporated, and the final residue dissolved in ether; (4) moist yeast is mixed with an equal quantity of water, and the mass extracted by pressure, the liquid obtained treated with ether, and the ethereal residue purified by repeated solution in ether and acetone.
A gamified pharmaceutical packaging, dispensing system, and methodology is disclosed. The innovative gamified smart packaging system and methodology provides a variety of incentives to patients and relevant teams to take their medications, on time, and at the correct dosage. The system comprises monitored pharmaceutical dispensing devices that communicate with a plurality of compute devices, or smartphones. Each time the patient dispenses the medicine from the dispensing device, a signal is transmitted to the compute device. Upon receiving the signal, the compute device records the dispensing event, calculates a specific &#34;score&#34; for that event, and reports the patient&#39;s cumulative &#34;score&#34; of successfully dispensing the medicine. If a dispensing event signal is not received in a timely fashion, the system sends a prompt to the patient to take their medication. Accumulating points by properly taking the prescribed medication allows the patient and/or team to be eligible to receive various benefits.
FIELD: biotechnology, medicine, medicinal microbiology. SUBSTANCE: invention relates to the strain of lactobacillus of species Lactobacillus acidophilus that can be used for preparing fermented-milk curative-dietetic foodstuffs. The strain Lactobacillus acidophilus N.V. Ep 317/402-X (author name is &#34;Balans- Narine&#34;) is obtained by selection of the parent culture Lactobacillus acidophilus N.V. Ep 317/402 &#34;Narine&#34; and directed selection by the following indices: -antagonistic activity relative to microorganisms causing gastroenteric diseases, in part, pathogenic bacteria Helicobacter pylori causing different forms of gastritis and stomach and duodenum ulcers; - ability to produce useful substances (vitamins, amino acids, antioxidants); - resistance of bacterial cell membrane structures to external effects (acidity, temperature and so on) providing retention of lactobacilli high titer in the storage process. The strain Lactobacillus acidophilus shows more broad spectrum of antagonistic activity, in part, relative to pathogenic bacteria Helicobacter pylori causing different forms of gastritis and stomach and duodenum ulcers and significantly more content of useful substances that are necessary for correction of dysbacteriosis and different gastroenteric diseases. EFFECT: valuable medicinal properties of strain and fermented-milk product. 4 tbl, 5 ex
This invention is directed to acylated amino acid amidyl pyrazoles and related compounds of Formula (I). The invention is also directed to a pharmaceutical formation comprising such compound or in a pharmaceutically acceptable salt form thereof. The invention is further directed to a method for inhibiting .beta.-amyloid peptide release and/or synthesis, a method for inhibiting .gamma.--secretase activity, and a method for treating neurological disorders associated with .beta.-amyloid peptide production. The method comprises administering to a host a pharmaceutical formulation comprising an effective amount of a compound of Formula (I). The compounds of Formula (I) are useful in the prevention and treatment of Alzheimer&#39;s disease.   (see formula I)
The present invention relates to a natural composition for preventing and treating Parkinson&#39;s disease, and more specifically, to a natural composition that enhances a motor improvement function in Parkinson&#39;s disease, formed of a composition obtained by mixing and extracting Uncaria rhynchophylla, Paeonia japonica, Panax ginseng, Magnolia officinalis Rehd. et Wils. Glycyrrhiza uralensis, Piper nigrum, and Spatholobus suberectus Dunn. The present invention provides a natural composition that enhances a motor improvement function in Parkinson&#39;s disease, formed of a composition obtained by mixing and extracting Uncaria rhynchophylla, Paeonia japonica, Panax ginseng, Magnolia officinalis Rehd. et Wils. Glycyrrhiza uralensis, Piper nigrum, and Spatholobus suberectus Dunn. In addition, the present invention provides a natural composition that enhances a motion improvement function in Parkinson&#39;s disease, formed by including any one or more of Chrysanthemum indicum, Phellodendron amurense Rupr and Dioscorea batatas and extracting the same. Furthermore, the present invention provides a pharmaceutical composition having a motor improvement function in Parkinson&#39;s disease, comprising the natural composition that enhances a motor improvement function in Parkinson&#39;s disease.
PROBLEM TO BE SOLVED: To obtain a new compound useful as an antibacterial agent or its intermediate. SOLUTION: The objective compound is a cleavage product of a phosphoglycolipid antibiotic substance of the formula I (R&lt;1&gt; is H; R&lt;2&gt; is a 5-55C alkyl). A cultured product of Bacillus DSM 4675 or its processed product, especially a separated enzyme is usable for the decomposition of a phosphoglycolipid antibiotic substance, especially antibiotic substances of moenomycin group. Moenomycin A is incubated with moenomycinase preferably at pH 8.2-8.3 and 49-51 deg.C to obtain the compounds of the formula II and III and the compound of the formula III is incubated with an MBase preferably at pH 6-8 and 35-37 deg.C for 24 hr to obtain the compound of the formula IV. The reaction product can be used as an antibiotic substance (e.g. the compound of the formula III) or a basic unit (e.g. the compound of the formula II and IV) in the synthesis of a transglycosylase inhibitor.
PURPOSE:To prepare a composite drug containing increased amount of drug per unit area and having industrial advantage, by crosslinking a surface of a polymer film, and laminating a mixture of a polymer and a specific transcutaneous drug to the other face of the film by coating or transfer. CONSTITUTION:The surface layer of one face of a polymer film into which a contacted drug can be permeated (e.g. polyvinyl acetate film) is crosslinked. The other face of the film is coated or transferred with a mixture obtained by adding a transcutaneous drug to a polymer having pressure-sensitive adhesivity at normal temperature, to form a laminated composite drug. The amount of the transcutaneous drug added to the polymer is more than the saturation solubility in the polymer. An acrylic copolymer is most suitable for industrial purpose. The transcutaneous drug is a solid at &gt;=0 deg.C, e.g. corticosteroids, analgesic and antiinflammatory agent an antibiotic substance, etc. The crystallization of the drug in the polymer layer is inhibited, the obtained drug can be applied surely to the skin, the drug can be absorbed easily through the skin, and the drug action can be controlled.
FIELD: medicine. 
     SUBSTANCE: invention refers to medicine, namely to therapy, balneotherapy. The method involves prescribing keeping diet No.8, taking radon baths. Individual patient&#39;s sensitivity to radon procedures shall be determined at first. That is ensured by measuring blood pressure and pulse rate on an empty stomach before taking a bath. Then the patient takes a bath with mineral water of thermal radon sources at water temperature approximately 38°C and has a rest for 30 minutes. Then blood pressure and pulse rate are measured once more. If observing pulse being unchanged or changed by ±10 beat/min and systolic and/or diastolic blood pressure being changed by ±10 mm Hg, the type I reaction is stated in the patient. If pulse is found to be changed by ±20 beat/min, and systolic and/or diastolic blood pressure has been changed by ±15 mm Hg, the type II reaction is observed. If pulse has been changed by ±30 beat/min, and systolic and/or diastolic blood pressure has been changed by ±20 mm Hg, the type III reaction is observed. The type I reaction requires the following bath-taking scheme: the first procedure - 5 minutes, the second one - 8 minutes, the third one - 10 minutes, all the following procedures - for 15 minutes. The type II reaction requires the following bath-taking scheme: the first procedure - 5 minutes, the second one - 8 minutes, the third one - 10 minutes, all the following procedures - for 12 minutes. The type III reaction requires the following bath-taking scheme: the first procedure - 5 minutes, the second one - 8 minutes, the third one - 10 minutes, all the following procedures - for 10 minutes. Radon bath is taken for two days running followed by the two-day pause. Before noon, two hours after breakfast, the patient moderately drinks radon water 200 ml, swims in the swimming pool for 40 minutes and undergoes a detensor-therapy. During afternoon, two hours after dinner, the patient moderately drinks radon water 200 ml and takes a bath with radon water; then a resonant-acoustic fluctuations procedure follows. The therapeutic course includes 10-15 baths. On the bath-free days, intestinal lavage is prescribed before noon, and hydromassage and body and face thalassotherapy are used during afternoon. 
     EFFECT: method provides manifested body weight reduction ensured by normalising action of external respiratory function and lipid metabolism. 
     3 cl, 1 tbl
PURPOSE:A percutaneous absorption pharmaceutical for external use, obtained by using a sympathomimetic beta-receptor agent (bronchodilator) and an animal or vegetable oil or organic acid ester or both which are liquid at a specific temperature or below together, and having improved percutaneous absorbability of the above-mentioned drug. CONSTITUTION:A percutaneous absorption pharmaeutical, obtained by incorporating a sympathomimetic beta-receptor agent clinically and widely used as a bronchodilator for bronchial asthma or chronic bronchitis, etc. e.g. isoproterenol or orciprenaline, with an animal or vegetable oil or organic acid ester or both which are liquid at &lt;=37 deg.C in an amount of preferably 1-100pts.wt. based on 1pts.wt. above-mentioned drug at 1:0.05-100 weight ratio between the above- mentioned animal or vegetable oil and/or ester and a base in using the above- mentioned sympathomimetic beta-receptor agent in the administration form of an easily administrable percutaneous absorption pharmaceutical for external use having high remedial effect, and capable of remarkably improving the percutaneous absorption of the above-mentioned drug exhibiting no effect by the well-known absorption promoter, e.g. salicylic acid.
PURPOSE: To provide a novel pharmaceutical compsn. in a form of nanocapsule colloid suspension liquid containing a surfactant dissolved in the liquid and plural nanocapsules having &lt;500 nm diameter comprising an oil layer of the oil suspended in the liquid. CONSTITUTION: The nanocapsule is essentially produced by capsuling a water phase comprising an active material as a therapeutic medicine in water and a soln. or suspension (pH between 1 to 7) of a surfactant. The wall of the nanocapsule consists of poly(alkyl 2-cyanoacrylate), wherein alkylradicals have 1 to 6 carbon atoms. The pharmaceutical compsn. is especially suitable for oral medication of polypeptide and polysaccharide.
A children&#39;s abdominal-distension constipation patch relates to traditional Chinese medicine compositions. The children&#39;s abdominal-distension constipation patch comprises a traditional Chinese medicine powder and a patch part. The traditional Chinese medicine powder comprises, in parts by mass, 30-90 parts of fructus gardeniae and 30-90 parts of radix et rhizoma rhei. The preparation method for the traditional Chinese medicine powder comprises selecting clean medicine materials in the formula, rinsing with water, airing, respectively grinding to form powders for usage, uniformly mixing the medicine powders and packaging, so as to obtain the traditional Chinese medicine powder, and putting the powder in a shade place and drying the powder. The usage method of the children&#39;s abdominal-distension constipation patch comprises blending the traditional Chinese medicine powder in a pack with warm water to form a paste, pasting on navel, and keeping the paste covering navel for 24 h. The patch is waterproof, and does not influence bathing if the patch is carefully protected. The patch is fast in effectiveness, extremely less in side effect, easily acceptable by children and convenient to operate, can be operated by a parent at home, does not influence diet and sleep, and guarantees that children well have a meal and sleep, and the disease is facilitated to be cured when children feel pleasure.
1. A composition comprising an anti-tumor drug conjugated to a water soluble polymer or metal chelator and wherein said a water soluble polymer or metal chelator is selected from the group consisting of poly (d-glutamic acid), poly (l-glutamic acid), poly (dlglutamic acid), poly (d-aspartic acid), poly (l-aspartic acid), poly (dl-aspartic acid)and copolymers thereof, where the anti-tumor drug is paclitaxel, docetaxel, etopside, teniposide camptothecin or epothilone. 2. The composition of claim 1 wherein the anti-tumor drug is selected from paclitaxel, docetaxe and camptothecin. 3. The composition of claim 2, wherein said polymer is further defined as a copolymer with polycaprolactone, polyglycolic acid and polylactic acid. 4. The composition of any preceding claim, wherein said polymer/copolymer has a molecular weight of from about 5,000 to about 100,000, preferably from about 20,000 to about 80,000. 5. The composition of any preceding claim, wherein said water soluble polymer is conjugated to the 2&#39;-and/or the 7-hydroxyl of paclitaxel or docetaxel. 6. The composition of any preceding claim, comprising from 2 to 35% by weight of said anti-tumor drug. 7. The composition of claim 1, wherein paclitaxel is conjugated with polyglutamic acid. 8. Use of said composition of any preceding claim of treating cancer for decreasing at least one symptom of a systemic autoimmune disease and for inhibiting arterial restenosis or arterial occlusion following vascular trauma. 9. Use of claim 8, wherein said cancer is breast cancer, ovarian cancer, malignant melanoma, lung cancer, gastric cancer, colon cancer, head and neck cancer or leukemia or or Kaposi&#39;s sarcoma.  10. An implantable medical device, in particular stent, wherein said device is coated with a composition comprising paclitaxel conjugated to water soluable polyamino acids in an amount effective to inhibit smooth muscle cell proliferation.
PCT No. PCT/FR89/00050 Sec. 371 Date Apr. 6, 1990 Sec. 102(e) Date Apr. 6, 1990 PCT Filed Feb. 8, 1989 PCT Pub. No. WO89/12065 PCT Pub. Date Dec. 14, 1989.The invention relates to a process for separating proteins from a fraction of human or animal plasma. According to this process, a solubilized fraction of cryoprecipitated plasma is subjected to a single stage of chromatography on a moderately ionic anion exchange resin permitting hydrophobic interactions to take place, which does not adsorb certain proteins and fixes others, which are then eluted by increasing the ionic strength of the buffer by the addition of NaCl. The process according to the invention makes it possible, in particular, to obtain a Factor VIII concentrate of high purity that can be used for the treatment of haemophilia A. The process also makes it possible to obtain concentrates of fibrinogen, Von Willebrand&#39;s factor and fibronectin.
edex® in the Treatment of Erectile Dysfunction

The dosage range of edex® for the treatment of erectile dysfunction is 1 to 40 mcg. The intracavernous injection should be given over a 5 to 10 second interval. In a study with a dose range of 1 to 20 mcg of edex®, the mean dose was 10.7 mcg at the end of the dose titration period. In two studies with a dose range of 1 to 40 mcg of edex®, the mean dose was 21.9 mcg at the end of the dose titration period. Doses greater than 40 mcg have not been studied. A &frac12;-inch, 27- to 30-gauge needle is generally recommended for the intracavernous injection. The patient is advised not to exceed the optimum edex® dose which was determined in the doctor's office. The lowest possible effective dose should always be used.
FIELD: veterinary medicine. SUBSTANCE: the strain is characterized by a complex of morphological and cultural-biochemical features. It represents straight and slightly curved rods with rounded edges 1X3-6 mcm being single, in pairs and in chains. Upon a broth, long and coiled filaments are formed consisted of several indivisible cells. It is characterized by polymorphism. Oval spores are developed which take up 1/2 - 2/3 cell size. They are located centrally or subterminally with no distinct sporangium bulging. Aerobes are mobile at 38 C optimal growth temperature. Rods are dyed positively according to Gram. Upon a meat-peptone agar, they are growing as grayish-white dull nontransparent flat folded dry colonies of rounded shape and average size (D=5- 10 mm). Colonies are tightly united with a substrate, at 2nd-3d having a yellow- colored shade. It releases catalase, acetoin and acethylmethylcarbon. It releases no indole and hydrogen sulfide. It reduces nitrates and nitrites, hydrolizes a starch. It hydrolizes no hippurate. It disintegrates glucose, saccharose, lactose and mannitol by developing an acid, not a gas. It releases proteolytic ferments, gelatin is diluted by a funnel, then - by layers. EFFECT: decreased average duration of therapy against the known &#34;Sporobacterine&#34; preparation. 2 ex _
A system and method is provided to allow multiple patients to receive peritoneal dialysis treatment at a walk-in facility without having to keep fresh dialysis solution on hand themselves. The walk-in facility is enabled to receive a peritoneal dialysis prescription from a patient, verify the prescription, determine the appropriate treatment for the patient, provide the patient with the appropriate dialysis solution in the appropriate amount, and enable the patient to undergo a dialysis treatment at the facility. The walk-in facility can also be enabled to monitor the patient&#39;s home dialysis treatment and to adjust the patient&#39;s treatment at the facility accordingly. The facility can be enabled to produce dialysis solution on demand by manufacturing the solution from solution components according to a patient&#39;s prescription. Moreover, the facility can use a sorbent system to regenerate effluent dialysis solution into fresh dialysis solution. In one embodiment, the peritoneal dialysis system includes (i) a fill container, and (ii) an energizing unit that removably accepts the fill container, the energizing unit including a sterilization source so configured and arranged relative to the fill container when accepted by the energizing unit to place fluid within the fill container in a physiologically safe condition for delivery to the peritoneal cavity of a patient. FIG. 8A 100-N r18 6a 88b 76 hc 8186b Al434 --,\ 188 Cc /1 t 16 -(432 474-46 466 4W 2 134 42 n 194
PURPOSE:To obtain an ameliorant for cerebral function, containing a pyrimidine derivative or salt thereof as an active ingredient and useful for dementias, cerebral degeneracies, stromal or functional cerebropathies. CONSTITUTION:The objective substance obtained by containing a compound expressed by formula I [n is 3-6; R2 and R3 are H, halogen, lower alkyl, hydroxy, etc.; R4 is H or lower alkyl; Y is formula II (R1 is H, lower alkyl, lower alkenyl, etc.; R5 and R6 are H or lower alkyl; m is 2 or 3), etc.] or an acid addition salt thereof as an active ingredient, mixing a formulating carrier therewith and preparing a pharmaceutical according to a conventional method. The above-mentioned pharmaceutical can be prepared in the form of an oral agent, injection, suppository, etc., and the does thereof is 0.01-50mg/kg/day. The compound expressed by formula I is obtained by reacting a compound expressed by formula III (X is leaving atom or group) with a compound expressed by formula IV (R1&#39; is H, lower alkyl, etc.) in the presence of a base (e.g. an alkali carbonate) in a solvent (e.g. alcohols) at 40-200 deg.C.